ALBERT

Description: The therapeutic application of in utero hematopoietic stem cell (HSC) transplantation (IUHSCT) is theoretically attractive for definitive treatment of congenital disease states. Investigating this technique in sheep, we have previously shown long-term engraftment and expression of both allogeneic and xenogeneic donor cells without cytoablation and, under appropriate conditions, without GVHD. The theoretical basis for IUHSCT is the well-recognized immune receptivity of the fetus to engraftment of donor cells. Engraftment and long-term expression of donor human and allogeneic sheep HSC reliably occur in the fetal sheep model if the IUHSCT is performed prior to day 71 of gestation (term: 145 days), during the period of presumed immuno-naïveté. Investigations using alternate animals have also noted that gestational age at transplantation is critical to achieving long-term engraftment, presumably as a result of inducing durable immune tolerance to the donor. Despite this presumption, however, the biologic explanation for fetal receptivity to donor engraftment and subsequent long-term tolerance following transplantation early in gestation is not known. In the present studies, we investigated the role fetal immune ontogeny plays in the induction of tolerance following IUHSCT in sheep. To this end, we performed parallel experiments examining engraftment receptivity of fetal sheep to allogeneic and xenogeneic HSC and the appearance of immune phenotypes in fetal sheep lymphoid organs at varying gestational ages (days 39 to birth), attempting to draw correlations between the appearance/absence of specific immune cells and the ability to achieve durable engraftment and immune tolerance. Engraftment receptivity was determined 60 days post-transplantation at different time points in sheep fetal gestation, while immune phenotypes were determined by flow cytometry using commercially available antibodies to immune cell surface markers. Our results indicate that the fetus is largely non-receptive to engraftment of both allogeneic and xenogeneic donor HSC prior to day 52 gestation and possesses a peak in engraftment receptivity between days 64–71 of gestation, which rapidly declines thereafter. With respect to the developing fetal immune system, the period of peak engraftment receptivity was associated with the expression of CD45 on all cells in the thymus. Double-positive and single-positive CD4 and CD8 cells began appearing in the thymus just prior (day 45 of gestation) to the beginning of the engraftment window, while single-positive CD4 or CD8 cells did not begin appearing in peripheral organs until late in the engraftment period, suggesting deletional mechanisms predominate during this time. In a similar fashion, surface IgM (sIgM)+ cells in the thymus were the first to express CD45, commencing expression around day 45 of gestation, with a comparable delay in the appearance of IgM+/CD45+ cells in the peripheral blood and spleen until late in the engraftment window. These findings support a central role for the thymus in multilineage immune cell maturation during the period of fetal transplantation receptivity. Further, they suggest that fetal engraftment receptivity/long-term engraftment and expression following IUHSCT is due to gestational age-dependent deletional tolerance. Further, our findings suggest that IUHSCT in humans may be more successful if performed during the comparable period in human gestation.

Description: Transplantation of hematopoietic stem cells into fetal sheep early in gestation (day (d) 55) (term gestation = 145d) results in long-term multi-lineage hemopoietic chimerism. We have proposed that the fetus is immunologically receptive at this time. However, our understanding of the mechanisms underlying this establishment of fetal tolerance remains poorly defined. We hypothesized that examination of developmental events in fetal immune ontogeny might provide insights into mechanisms underlying fetal tolerance formation. To this end we have previously reported the early appearance of cells phenotypically consistent with T regulatory cells (CD4+/CD25+) and multilineage expression of the CD45 isoform CD45R early in gestation (d40–65). Here, we extend our observations on B lineage cell distribution and relative CD45 isoform expression during gestation. The two commercially-available ovine CD45 antibodies are CD45 (immunoprecipitates proteins of MW 225, 210, and 190 kD, (Immunology.1985; 55:347–353)) and CD45R (immunoprecipitates a single protein of MW 220 kD (Cell. Immunol.1987;110:46–55)). Using dual-color flow cytometry, cells from fetal thymus, intestine, lung, spleen, bone/bone marrow, and peripheral blood (PB) were analyzed for expression of surface IgM, CD45 and CD45R from d39 to two days after birth. Surface IgM+ cells in the thymus were observed to be as high as 28% at d39 of gestation (uniformly CD45R+/CD45−). This rapidly dissipated to less than 1% after d65 of gestation, although IgM+ cells were observed as late as two days after birth. All IgM+ cells expressed CD45R in all organs tested but relative CD45 expression varied by gestational age and organ. Subsequent sampling noted rapid onset of CD45 coexpression on 〉70% of detectable thymic surface IgM+ cells throughout gestation. Similarly, splenic IgM+ cells co-expressed high levels of CD45 while PB IgM+ cells had delayed CD45 expression (beyond d65). Bone/bone marrow showed variable coexpression of CD45 throughout gestation. By contrast, surface IgM+ cells in lung and intestine maintained CD45R expression without coexpression of CD45 prior to birth. We have previously reported humoral tolerance to retroviral vector transgene products transplanted at d55–60 (Blood.2001; 97:3417–3423). Further understanding of CD45 isoform expression patterns and relative organ distribution of surface IgM+ cell populations during the time of immune receptivity in the sheep may provide insight into fetal transplantation tolerance.